[{"arm_notes": "", "treatment_id": null, "treatment_name": "EPOCIM (Study group): 200;000 IU of ior\u00aeEPOCIM intravenously (IV); divided into 5 administrations of 40;000 IU; diluted in 100 ml of physiological saline; to be infused for 1 hour; on days 0; 3; 10; 17 and 21. They will also receive the best support treatment for cardiovascular; kidney and/or respiratory disorders post-COVID-19 available in Cuba during the development of the research. This can include statins; antischemic drugs; antiarrhythmics; antiplatelet drugs; etc. If respiratory sequelae; treatment may also include steroids (without exceeding a total daily dose of 60 mg / day for 14 days and / or weekly gradual reduction); bronchodilators; antibiotics in case of infection; oxygen therapy and / or pulmonary rehabilitation. The research team should assess the possible drug combinations; according to the type of sequelae and characteristics of the available drugs.Control group: They will receive the best support treatment for cardiovascular; kidney and/or respiratory disorders post-COVID-19 available in Cuba during the development of the research.In each group the patients will be divided in 4 subgroups according to the type of sequelae:Subgroup I: Patients with cardiovascular sequelaeSubgroup II: Patients with kidney sequelaeSubgroup III: Patients with respiratory sequelaeSubgroup IV: Patients with mixed sequelae: cardiovascular; kidney and / or respiratory.;Erythropoietin ;Infusions; Intravenous;ior\u00ae EPOCIM", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 473, "treatment_name": "Epoetin alfa", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "EPOCIM (Study group): 200;000 IU of ior\u00aeEPOCIM intravenously (IV); divided into 5 administrations of 40;000 IU; diluted in 100 ml of physiological saline; to be infused for 1 hour; on days 0; 3; 10; 17 and 21. Control group: They will receive the best support treatment for cardiovascular; kidney and/or respiratory disorders post-COVID-19 available in Cuba during the development of the research.In each group the patients will be divided in 3 strata according to the type of sequelae:Stratum I: Patients with cardiovascular sequelaeStratum II: Patients with kidney sequelaeStratum III: Patients with mixed sequelae: cardiovascular; kidney and / or respiratory.In each stratum there will be 40 patients; 30 in the experimental treated group and 10 in the control group.;Erythropoietin ;Infusions; Intravenous;ior\u00ae EPOCIM", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]